BioCryst Pharmaceuticals | BCRX - Operating Expenses


BioCryst Pharmaceuticals reported $-553.84M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Chugai Pharma JPY 162.98B 14.31B Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026